SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT 1934
DATE OF REPORT: MAY 15, 2003
TITAN PHARMACEUTICALS, INC.
---------------------------
(Exact name of registrant as specified in charter)
DELAWARE 0-27436 94-3171940
---------------------------- ------------------------ ------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 244-4990
--------------
--------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS
The registrant hereby incorporates by reference the press release
dated May 15, 2003 attached hereto as Exhibit 99.1 ("Titan Reports First Quarter
2003 Results").
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release - Titan Reports First Quarter 2003 Results
2
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TITAN PHARMACEUTICALS, INC.
By: /s/ Robert E. Farrell
-------------------------------------------
Robert E. Farrell, Executive Vice President
and Chief Financial Officer
Dated: May 15, 2003
3
--------------------------------------------------------------------------------